Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Menopause | 97 | 2025 | 303 | 20.140 |
Why?
|
Hot Flashes | 36 | 2025 | 81 | 9.180 |
Why?
|
Infertility, Female | 47 | 2024 | 105 | 8.820 |
Why?
|
Estrogen Replacement Therapy | 32 | 2025 | 142 | 6.450 |
Why?
|
Women's Health | 43 | 2025 | 363 | 6.220 |
Why?
|
Estradiol | 59 | 2025 | 497 | 5.860 |
Why?
|
Follicle Stimulating Hormone | 62 | 2024 | 239 | 5.830 |
Why?
|
Polycystic Ovary Syndrome | 35 | 2024 | 166 | 5.810 |
Why?
|
Perimenopause | 25 | 2024 | 63 | 5.720 |
Why?
|
Menstrual Cycle | 36 | 2024 | 124 | 5.370 |
Why?
|
Luteinizing Hormone | 55 | 2024 | 178 | 5.370 |
Why?
|
Endocrinology | 9 | 2023 | 74 | 4.790 |
Why?
|
Ovary | 26 | 2024 | 214 | 4.470 |
Why?
|
Postmenopause | 35 | 2025 | 370 | 4.160 |
Why?
|
Progesterone | 39 | 2025 | 244 | 3.950 |
Why?
|
Anti-Mullerian Hormone | 16 | 2023 | 53 | 3.930 |
Why?
|
Infertility | 13 | 2024 | 50 | 3.820 |
Why?
|
Reproductive Medicine | 8 | 2023 | 14 | 3.660 |
Why?
|
Live Birth | 23 | 2024 | 55 | 3.630 |
Why?
|
Metabolic Syndrome | 16 | 2024 | 340 | 3.390 |
Why?
|
Female | 355 | 2025 | 68127 | 3.340 |
Why?
|
Estrogens | 22 | 2024 | 354 | 3.180 |
Why?
|
Obesity | 33 | 2024 | 2860 | 2.980 |
Why?
|
Ovulation Induction | 30 | 2024 | 55 | 2.960 |
Why?
|
Fertility | 16 | 2024 | 162 | 2.910 |
Why?
|
Primary Ovarian Insufficiency | 14 | 2021 | 34 | 2.890 |
Why?
|
Fertilization in Vitro | 19 | 2024 | 76 | 2.750 |
Why?
|
Humans | 376 | 2025 | 128524 | 2.640 |
Why?
|
Hormones | 13 | 2021 | 140 | 2.620 |
Why?
|
Androgens | 15 | 2021 | 174 | 2.600 |
Why?
|
Luteal Phase | 16 | 2020 | 44 | 2.490 |
Why?
|
Reproduction | 9 | 2022 | 201 | 2.280 |
Why?
|
Adult | 196 | 2025 | 35315 | 2.250 |
Why?
|
Vasomotor System | 9 | 2025 | 43 | 2.220 |
Why?
|
Biomarkers | 36 | 2025 | 3881 | 2.150 |
Why?
|
Aging | 28 | 2024 | 1770 | 2.120 |
Why?
|
Receptors, Neurokinin-3 | 4 | 2024 | 7 | 2.030 |
Why?
|
Depression | 13 | 2024 | 1289 | 1.960 |
Why?
|
Cryopreservation | 6 | 2024 | 98 | 1.930 |
Why?
|
Heterocyclic Compounds, 2-Ring | 6 | 2024 | 8 | 1.930 |
Why?
|
Endometrium | 15 | 2020 | 61 | 1.910 |
Why?
|
Ovulation | 14 | 2018 | 40 | 1.850 |
Why?
|
Estrogens, Conjugated (USP) | 13 | 2025 | 46 | 1.850 |
Why?
|
Testosterone | 24 | 2021 | 378 | 1.820 |
Why?
|
Ovarian Follicle | 10 | 2024 | 63 | 1.810 |
Why?
|
Fertility Agents, Female | 14 | 2022 | 19 | 1.810 |
Why?
|
Pregnancy | 73 | 2024 | 6297 | 1.800 |
Why?
|
Menopause, Premature | 4 | 2021 | 9 | 1.790 |
Why?
|
Gonadal Steroid Hormones | 13 | 2024 | 132 | 1.770 |
Why?
|
Pregnancy Rate | 22 | 2024 | 60 | 1.710 |
Why?
|
Thiadiazoles | 5 | 2024 | 24 | 1.680 |
Why?
|
Cardiovascular Diseases | 23 | 2024 | 2018 | 1.650 |
Why?
|
Hypothalamo-Hypophyseal System | 6 | 2024 | 176 | 1.640 |
Why?
|
Diet, High-Fat | 2 | 2024 | 238 | 1.620 |
Why?
|
Double-Blind Method | 34 | 2025 | 1860 | 1.610 |
Why?
|
Sexual Dysfunction, Physiological | 9 | 2018 | 67 | 1.600 |
Why?
|
Hormone Replacement Therapy | 9 | 2022 | 91 | 1.590 |
Why?
|
Fatty Acids, Nonesterified | 2 | 2024 | 159 | 1.570 |
Why?
|
Quality of Life | 18 | 2024 | 2680 | 1.540 |
Why?
|
Infertility, Male | 11 | 2022 | 61 | 1.520 |
Why?
|
Mental Health | 3 | 2024 | 684 | 1.470 |
Why?
|
Middle Aged | 123 | 2025 | 30893 | 1.420 |
Why?
|
Carotid Intima-Media Thickness | 10 | 2021 | 91 | 1.400 |
Why?
|
Premenopause | 14 | 2022 | 127 | 1.380 |
Why?
|
Amenorrhea | 12 | 2017 | 28 | 1.340 |
Why?
|
Pregnanediol | 10 | 2020 | 12 | 1.340 |
Why?
|
Gonadotropin-Releasing Hormone | 16 | 2022 | 207 | 1.320 |
Why?
|
Vagina | 3 | 2020 | 175 | 1.310 |
Why?
|
Vaginal Diseases | 3 | 2020 | 22 | 1.270 |
Why?
|
Estrone | 11 | 2024 | 37 | 1.260 |
Why?
|
Hypothalamus | 10 | 2014 | 144 | 1.260 |
Why?
|
Endocrinologists | 3 | 2023 | 12 | 1.260 |
Why?
|
Body Mass Index | 34 | 2022 | 2262 | 1.240 |
Why?
|
Pregnancy Outcome | 11 | 2024 | 383 | 1.240 |
Why?
|
Hormone Antagonists | 2 | 2021 | 30 | 1.200 |
Why?
|
Sleep Wake Disorders | 7 | 2024 | 249 | 1.180 |
Why?
|
Inhibins | 8 | 2018 | 45 | 1.170 |
Why?
|
Embryo Transfer | 10 | 2024 | 33 | 1.170 |
Why?
|
Prospective Studies | 47 | 2025 | 7043 | 1.170 |
Why?
|
Gynecology | 2 | 2021 | 175 | 1.140 |
Why?
|
Atherosclerosis | 6 | 2024 | 405 | 1.100 |
Why?
|
Endometriosis | 4 | 2022 | 48 | 1.090 |
Why?
|
Anovulation | 7 | 2015 | 8 | 1.080 |
Why?
|
Hyperlipidemias | 5 | 2022 | 126 | 1.070 |
Why?
|
Randomized Controlled Trials as Topic | 20 | 2024 | 1358 | 1.070 |
Why?
|
Uterus | 4 | 2019 | 205 | 1.040 |
Why?
|
Treatment Outcome | 40 | 2024 | 10163 | 1.030 |
Why?
|
Patient Selection | 7 | 2021 | 661 | 0.990 |
Why?
|
Clomiphene | 9 | 2021 | 15 | 0.980 |
Why?
|
Hyperinsulinism | 3 | 2022 | 119 | 0.980 |
Why?
|
Sex Hormone-Binding Globulin | 15 | 2025 | 53 | 0.970 |
Why?
|
Young Adult | 37 | 2024 | 12320 | 0.970 |
Why?
|
Aromatase Inhibitors | 3 | 2020 | 52 | 0.960 |
Why?
|
Insulin Resistance | 11 | 2025 | 1166 | 0.950 |
Why?
|
Insulin | 12 | 2025 | 2318 | 0.950 |
Why?
|
Adipose Tissue | 4 | 2024 | 591 | 0.920 |
Why?
|
Preconception Care | 2 | 2024 | 40 | 0.910 |
Why?
|
United States | 51 | 2025 | 13876 | 0.910 |
Why?
|
Follicle Stimulating Hormone, Human | 3 | 2022 | 11 | 0.900 |
Why?
|
Adipokines | 1 | 2024 | 46 | 0.890 |
Why?
|
Fertility Preservation | 1 | 2024 | 54 | 0.890 |
Why?
|
HIV Infections | 17 | 2024 | 2703 | 0.880 |
Why?
|
Salpingo-oophorectomy | 1 | 2024 | 18 | 0.880 |
Why?
|
Biomedical Research | 4 | 2023 | 646 | 0.880 |
Why?
|
Life Cycle Stages | 1 | 2023 | 34 | 0.880 |
Why?
|
Weight Loss | 6 | 2024 | 723 | 0.860 |
Why?
|
Glucose Tolerance Test | 2 | 2024 | 356 | 0.860 |
Why?
|
Hypogonadism | 9 | 2024 | 82 | 0.850 |
Why?
|
Menarche | 2 | 2017 | 58 | 0.840 |
Why?
|
Gonadotropins | 5 | 2020 | 37 | 0.840 |
Why?
|
Longitudinal Studies | 25 | 2020 | 2697 | 0.830 |
Why?
|
Aromatase | 3 | 2014 | 31 | 0.820 |
Why?
|
Progestins | 4 | 2017 | 78 | 0.820 |
Why?
|
Ovarian Reserve | 3 | 2020 | 13 | 0.800 |
Why?
|
Drug Compounding | 3 | 2021 | 95 | 0.800 |
Why?
|
Irritable Mood | 3 | 2018 | 49 | 0.800 |
Why?
|
Corpus Luteum | 8 | 2017 | 20 | 0.790 |
Why?
|
Lipids | 7 | 2023 | 624 | 0.780 |
Why?
|
Pituitary Gland | 6 | 2021 | 148 | 0.780 |
Why?
|
Sexual Health | 1 | 2023 | 53 | 0.780 |
Why?
|
Risk Factors | 49 | 2024 | 9727 | 0.770 |
Why?
|
Health Knowledge, Attitudes, Practice | 4 | 2021 | 1271 | 0.770 |
Why?
|
Cytokines | 4 | 2024 | 1985 | 0.770 |
Why?
|
Leiomyoma | 5 | 2025 | 74 | 0.770 |
Why?
|
Abortion, Spontaneous | 8 | 2024 | 100 | 0.740 |
Why?
|
Cohort Studies | 30 | 2024 | 5369 | 0.740 |
Why?
|
Pregnancy Complications | 3 | 2024 | 488 | 0.740 |
Why?
|
Administration, Cutaneous | 12 | 2023 | 123 | 0.740 |
Why?
|
Fetal Research | 1 | 2021 | 3 | 0.730 |
Why?
|
Research Subjects | 1 | 2021 | 42 | 0.730 |
Why?
|
Soybean Oil | 1 | 2021 | 14 | 0.730 |
Why?
|
Age Factors | 22 | 2023 | 3117 | 0.730 |
Why?
|
Embryo, Mammalian | 1 | 2022 | 226 | 0.730 |
Why?
|
Federal Government | 1 | 2021 | 26 | 0.730 |
Why?
|
Sleep Initiation and Maintenance Disorders | 4 | 2018 | 147 | 0.720 |
Why?
|
Adolescent | 49 | 2024 | 20213 | 0.720 |
Why?
|
Hydrocortisone | 4 | 2022 | 301 | 0.720 |
Why?
|
Hand Strength | 1 | 2021 | 113 | 0.710 |
Why?
|
Bicycling | 1 | 2021 | 118 | 0.700 |
Why?
|
Premature Birth | 4 | 2024 | 311 | 0.700 |
Why?
|
Symptom Assessment | 2 | 2021 | 125 | 0.690 |
Why?
|
Feasibility Studies | 1 | 2024 | 860 | 0.690 |
Why?
|
Sleep | 9 | 2021 | 672 | 0.670 |
Why?
|
Cross-Sectional Studies | 30 | 2022 | 5040 | 0.670 |
Why?
|
Ultrasonography | 6 | 2018 | 723 | 0.670 |
Why?
|
Longevity | 1 | 2021 | 149 | 0.670 |
Why?
|
Reproductive Health | 3 | 2023 | 85 | 0.660 |
Why?
|
Obstetrics | 1 | 2021 | 160 | 0.660 |
Why?
|
Phospholipids | 1 | 2021 | 209 | 0.650 |
Why?
|
Practice Guidelines as Topic | 3 | 2016 | 1490 | 0.640 |
Why?
|
Spatial Memory | 1 | 2019 | 21 | 0.620 |
Why?
|
Body Composition | 10 | 2024 | 656 | 0.620 |
Why?
|
Hysterosalpingography | 1 | 2018 | 6 | 0.620 |
Why?
|
Liver | 4 | 2024 | 1827 | 0.610 |
Why?
|
Sexuality | 1 | 2018 | 31 | 0.610 |
Why?
|
Hypothalamic Diseases | 3 | 2017 | 18 | 0.610 |
Why?
|
Ovarian Hyperstimulation Syndrome | 3 | 2008 | 8 | 0.610 |
Why?
|
Menstruation | 10 | 2024 | 44 | 0.600 |
Why?
|
Anxiety | 5 | 2024 | 949 | 0.590 |
Why?
|
Thyrotropin | 4 | 2024 | 109 | 0.590 |
Why?
|
Life Style | 10 | 2024 | 459 | 0.580 |
Why?
|
Military Personnel | 1 | 2024 | 517 | 0.580 |
Why?
|
Phenotype | 5 | 2024 | 3050 | 0.570 |
Why?
|
Chorionic Gonadotropin | 10 | 2024 | 80 | 0.570 |
Why?
|
Insemination, Artificial | 5 | 2022 | 12 | 0.570 |
Why?
|
Abortifacient Agents, Nonsteroidal | 3 | 2024 | 21 | 0.560 |
Why?
|
Watchful Waiting | 3 | 2024 | 65 | 0.550 |
Why?
|
Methotrexate | 5 | 2024 | 249 | 0.540 |
Why?
|
Substance-Related Disorders | 6 | 2009 | 1011 | 0.540 |
Why?
|
Hyperandrogenism | 5 | 2024 | 18 | 0.540 |
Why?
|
Hypopituitarism | 2 | 2014 | 15 | 0.530 |
Why?
|
Hysterectomy | 5 | 2023 | 119 | 0.530 |
Why?
|
Health Surveys | 5 | 2011 | 492 | 0.530 |
Why?
|
Fetus | 1 | 2021 | 758 | 0.530 |
Why?
|
Circadian Rhythm | 3 | 2017 | 405 | 0.530 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2011 | 280 | 0.520 |
Why?
|
Pregnancy Trimester, First | 2 | 2019 | 135 | 0.520 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2016 | 26 | 0.510 |
Why?
|
Cumulus Cells | 2 | 2015 | 6 | 0.510 |
Why?
|
Cognition | 10 | 2022 | 1107 | 0.500 |
Why?
|
Adiposity | 4 | 2020 | 505 | 0.500 |
Why?
|
Levonorgestrel | 1 | 2015 | 37 | 0.500 |
Why?
|
Overweight | 5 | 2014 | 525 | 0.490 |
Why?
|
Uterine Hemorrhage | 3 | 2021 | 34 | 0.490 |
Why?
|
Sweating | 4 | 2018 | 40 | 0.490 |
Why?
|
Insemination, Artificial, Heterologous | 1 | 2015 | 2 | 0.490 |
Why?
|
Azoospermia | 1 | 2015 | 5 | 0.480 |
Why?
|
Tandem Mass Spectrometry | 2 | 2015 | 450 | 0.480 |
Why?
|
Surveys and Questionnaires | 20 | 2022 | 5346 | 0.480 |
Why?
|
Blood Chemical Analysis | 1 | 2015 | 96 | 0.460 |
Why?
|
Bone Density | 7 | 2011 | 476 | 0.460 |
Why?
|
Pulsatile Flow | 3 | 2011 | 59 | 0.460 |
Why?
|
Vulvodynia | 1 | 2014 | 2 | 0.450 |
Why?
|
Nitriles | 5 | 2015 | 160 | 0.450 |
Why?
|
Granulosa Cells | 4 | 2021 | 32 | 0.450 |
Why?
|
Time Factors | 20 | 2024 | 6503 | 0.440 |
Why?
|
Blood Proteins | 1 | 2015 | 236 | 0.440 |
Why?
|
Triazoles | 5 | 2015 | 151 | 0.430 |
Why?
|
Indoles | 1 | 2016 | 367 | 0.420 |
Why?
|
Cross-Over Studies | 4 | 2022 | 513 | 0.420 |
Why?
|
Pregnancy, Multiple | 4 | 2015 | 15 | 0.420 |
Why?
|
Osteoporosis | 1 | 2016 | 233 | 0.420 |
Why?
|
Pregnancy, Ectopic | 4 | 2024 | 54 | 0.420 |
Why?
|
Male | 65 | 2024 | 62883 | 0.410 |
Why?
|
Solubility | 2 | 2023 | 229 | 0.410 |
Why?
|
Follow-Up Studies | 17 | 2025 | 4898 | 0.400 |
Why?
|
Insemination, Artificial, Homologous | 3 | 2021 | 3 | 0.390 |
Why?
|
Parity | 2 | 2011 | 120 | 0.390 |
Why?
|
Uterine Neoplasms | 3 | 2025 | 102 | 0.390 |
Why?
|
Follicular Phase | 12 | 2014 | 40 | 0.390 |
Why?
|
Complementary Therapies | 3 | 2022 | 86 | 0.390 |
Why?
|
Stress, Psychological | 8 | 2018 | 1058 | 0.390 |
Why?
|
Cell Cycle | 1 | 2015 | 581 | 0.380 |
Why?
|
Prolactin | 4 | 2022 | 97 | 0.380 |
Why?
|
Aged | 25 | 2025 | 21971 | 0.380 |
Why?
|
Human Growth Hormone | 2 | 2022 | 44 | 0.370 |
Why?
|
Plaque, Atherosclerotic | 2 | 2024 | 55 | 0.370 |
Why?
|
Intracranial Thrombosis | 1 | 2011 | 16 | 0.370 |
Why?
|
Prevalence | 13 | 2019 | 2549 | 0.370 |
Why?
|
Fallopian Tubes | 3 | 2018 | 31 | 0.360 |
Why?
|
Antiretroviral Therapy, Highly Active | 5 | 2008 | 266 | 0.360 |
Why?
|
Endocrine System | 1 | 2011 | 20 | 0.360 |
Why?
|
Inflammation | 4 | 2024 | 2664 | 0.360 |
Why?
|
Weight Gain | 5 | 2020 | 505 | 0.350 |
Why?
|
Uterine Diseases | 2 | 2007 | 15 | 0.350 |
Why?
|
Coronary Artery Disease | 4 | 2019 | 677 | 0.340 |
Why?
|
Logistic Models | 14 | 2015 | 1975 | 0.340 |
Why?
|
Reproductive Techniques, Assisted | 3 | 2021 | 35 | 0.330 |
Why?
|
Activins | 3 | 2005 | 27 | 0.330 |
Why?
|
Exercise | 3 | 2022 | 1937 | 0.330 |
Why?
|
Diabetes Mellitus | 4 | 2025 | 1001 | 0.330 |
Why?
|
Regression Analysis | 7 | 2020 | 983 | 0.330 |
Why?
|
Odds Ratio | 14 | 2015 | 1022 | 0.330 |
Why?
|
Oocyte Donation | 1 | 2009 | 4 | 0.320 |
Why?
|
Prognosis | 14 | 2020 | 3780 | 0.320 |
Why?
|
Vulva | 1 | 2009 | 23 | 0.320 |
Why?
|
Trinucleotide Repeats | 1 | 2009 | 25 | 0.320 |
Why?
|
Incidence | 9 | 2025 | 2619 | 0.320 |
Why?
|
Multicenter Studies as Topic | 8 | 2022 | 285 | 0.320 |
Why?
|
Administration, Oral | 8 | 2020 | 757 | 0.320 |
Why?
|
Lactation | 2 | 2024 | 170 | 0.320 |
Why?
|
Fertility Agents | 2 | 2020 | 2 | 0.310 |
Why?
|
Luteal Cells | 1 | 2008 | 2 | 0.310 |
Why?
|
Multivariate Analysis | 13 | 2015 | 1494 | 0.310 |
Why?
|
Semen | 4 | 2022 | 19 | 0.310 |
Why?
|
Signal Transduction | 3 | 2021 | 4829 | 0.310 |
Why?
|
Fragile X Mental Retardation Protein | 1 | 2009 | 56 | 0.310 |
Why?
|
Pituitary Hormone-Releasing Hormones | 6 | 1989 | 10 | 0.310 |
Why?
|
Administration, Intravaginal | 2 | 2020 | 17 | 0.300 |
Why?
|
Ovariectomy | 3 | 2023 | 139 | 0.300 |
Why?
|
Mentors | 1 | 2010 | 174 | 0.300 |
Why?
|
Evidence-Based Medicine | 5 | 2017 | 717 | 0.300 |
Why?
|
Breast Neoplasms | 4 | 2022 | 2139 | 0.300 |
Why?
|
Carotid Artery Diseases | 2 | 2020 | 65 | 0.300 |
Why?
|
Bone Remodeling | 2 | 2008 | 74 | 0.300 |
Why?
|
Mood Disorders | 3 | 2015 | 118 | 0.300 |
Why?
|
Vitamin D Deficiency | 2 | 2021 | 177 | 0.290 |
Why?
|
Bone Diseases, Metabolic | 1 | 2008 | 60 | 0.290 |
Why?
|
Adaptation, Psychological | 3 | 2018 | 612 | 0.290 |
Why?
|
Oocyte Retrieval | 3 | 2015 | 12 | 0.290 |
Why?
|
Polyps | 1 | 2007 | 11 | 0.290 |
Why?
|
Risk Assessment | 12 | 2024 | 3256 | 0.290 |
Why?
|
Metformin | 3 | 2012 | 311 | 0.280 |
Why?
|
Pericardium | 3 | 2019 | 54 | 0.280 |
Why?
|
Virilism | 1 | 2007 | 5 | 0.280 |
Why?
|
Vitamin D | 3 | 2021 | 381 | 0.280 |
Why?
|
Non-alcoholic Fatty Liver Disease | 2 | 2023 | 259 | 0.280 |
Why?
|
Antioxidants | 2 | 2021 | 543 | 0.270 |
Why?
|
Pituitary-Adrenal System | 3 | 2017 | 143 | 0.270 |
Why?
|
Dehydroepiandrosterone Sulfate | 6 | 2011 | 46 | 0.270 |
Why?
|
Reproductive Techniques | 3 | 2001 | 6 | 0.270 |
Why?
|
Fertilization | 3 | 2022 | 42 | 0.270 |
Why?
|
Child | 24 | 2024 | 20721 | 0.260 |
Why?
|
Metabolome | 1 | 2009 | 318 | 0.260 |
Why?
|
Specimen Handling | 3 | 2018 | 165 | 0.260 |
Why?
|
Autoimmunity | 2 | 2024 | 860 | 0.260 |
Why?
|
Attitude to Health | 3 | 2009 | 430 | 0.260 |
Why?
|
Pilot Projects | 5 | 2020 | 1558 | 0.250 |
Why?
|
Affect | 3 | 2018 | 285 | 0.250 |
Why?
|
Insulin-Like Growth Factor I | 5 | 2022 | 307 | 0.250 |
Why?
|
Glucose | 3 | 2024 | 983 | 0.250 |
Why?
|
Reference Values | 9 | 2020 | 780 | 0.250 |
Why?
|
New York City | 6 | 2010 | 80 | 0.250 |
Why?
|
Leuprolide | 4 | 1998 | 19 | 0.250 |
Why?
|
Infant, Newborn | 10 | 2024 | 5687 | 0.250 |
Why?
|
Bariatric Surgery | 1 | 2008 | 190 | 0.240 |
Why?
|
Cholesterol, LDL | 2 | 2010 | 361 | 0.240 |
Why?
|
Atrophy | 2 | 2020 | 172 | 0.240 |
Why?
|
Case-Control Studies | 7 | 2020 | 3326 | 0.240 |
Why?
|
Recovery of Function | 2 | 2008 | 643 | 0.240 |
Why?
|
Oxidative Stress | 2 | 2021 | 1188 | 0.240 |
Why?
|
Contraceptive Agents, Female | 2 | 2016 | 78 | 0.240 |
Why?
|
Dehydroepiandrosterone | 5 | 2016 | 51 | 0.230 |
Why?
|
Follistatin | 1 | 2004 | 12 | 0.230 |
Why?
|
Lipolysis | 1 | 2024 | 40 | 0.230 |
Why?
|
Age of Onset | 3 | 2017 | 493 | 0.230 |
Why?
|
Biology | 2 | 2023 | 83 | 0.230 |
Why?
|
Pituitary Hormones, Anterior | 1 | 2024 | 7 | 0.230 |
Why?
|
Ideal Body Weight | 1 | 2024 | 4 | 0.230 |
Why?
|
Socioeconomic Factors | 7 | 2013 | 1197 | 0.230 |
Why?
|
Neoplasms | 4 | 2024 | 2465 | 0.230 |
Why?
|
C-Reactive Protein | 4 | 2022 | 396 | 0.230 |
Why?
|
Vascular Calcification | 2 | 2019 | 107 | 0.230 |
Why?
|
Thyroid Gland | 1 | 2024 | 94 | 0.230 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2021 | 3618 | 0.230 |
Why?
|
Focus Groups | 2 | 2024 | 448 | 0.230 |
Why?
|
Academic Medical Centers | 4 | 2021 | 473 | 0.230 |
Why?
|
Ovum | 1 | 2024 | 29 | 0.220 |
Why?
|
Pediatric Obesity | 2 | 2024 | 572 | 0.220 |
Why?
|
Blood Glucose | 7 | 2025 | 2092 | 0.220 |
Why?
|
Physical Conditioning, Human | 1 | 2024 | 39 | 0.220 |
Why?
|
Embryo Culture Techniques | 1 | 2024 | 11 | 0.220 |
Why?
|
Alanine Transaminase | 1 | 2024 | 150 | 0.220 |
Why?
|
Skin Aging | 2 | 2016 | 20 | 0.220 |
Why?
|
Diet, Fat-Restricted | 1 | 2024 | 79 | 0.220 |
Why?
|
Gastrointestinal Microbiome | 2 | 2022 | 635 | 0.220 |
Why?
|
Quality-Adjusted Life Years | 1 | 2024 | 108 | 0.220 |
Why?
|
Clinical Trials as Topic | 4 | 2020 | 998 | 0.220 |
Why?
|
Endometrial Hyperplasia | 1 | 2023 | 11 | 0.210 |
Why?
|
Oligomenorrhea | 2 | 2014 | 8 | 0.210 |
Why?
|
Bone Resorption | 2 | 2015 | 81 | 0.210 |
Why?
|
Glucose Intolerance | 1 | 2024 | 142 | 0.210 |
Why?
|
Drug Therapy, Combination | 5 | 2018 | 1009 | 0.210 |
Why?
|
Cell Cycle Proteins | 1 | 2007 | 580 | 0.210 |
Why?
|
Dyspareunia | 2 | 2016 | 8 | 0.210 |
Why?
|
National Institute of Child Health and Human Development (U.S.) | 2 | 2023 | 9 | 0.210 |
Why?
|
Retrospective Studies | 14 | 2024 | 14460 | 0.210 |
Why?
|
Ovulation Detection | 1 | 2002 | 1 | 0.210 |
Why?
|
Carotid Stenosis | 1 | 2024 | 85 | 0.210 |
Why?
|
Fractures, Bone | 2 | 2008 | 417 | 0.210 |
Why?
|
Interleukin-6 | 2 | 2022 | 716 | 0.210 |
Why?
|
White Matter | 1 | 2025 | 132 | 0.210 |
Why?
|
Animals | 15 | 2024 | 34501 | 0.200 |
Why?
|
Insulin-Like Growth Factor Binding Protein 1 | 2 | 2019 | 26 | 0.200 |
Why?
|
Dilatation and Curettage | 2 | 2021 | 12 | 0.200 |
Why?
|
Magnetic Resonance Imaging | 3 | 2025 | 3366 | 0.200 |
Why?
|
Asymptomatic Diseases | 3 | 2018 | 85 | 0.200 |
Why?
|
Anti-HIV Agents | 2 | 2005 | 747 | 0.200 |
Why?
|
Simvastatin | 1 | 2002 | 55 | 0.200 |
Why?
|
Fatty Liver | 1 | 2024 | 232 | 0.200 |
Why?
|
Cuba | 3 | 2010 | 11 | 0.190 |
Why?
|
Reimbursement Mechanisms | 2 | 2001 | 84 | 0.190 |
Why?
|
Central America | 3 | 2010 | 21 | 0.190 |
Why?
|
Goals | 1 | 2023 | 162 | 0.190 |
Why?
|
Smoking | 6 | 2015 | 1463 | 0.190 |
Why?
|
Referral and Consultation | 3 | 2016 | 727 | 0.190 |
Why?
|
Puerto Rico | 3 | 2010 | 52 | 0.190 |
Why?
|
South America | 3 | 2010 | 56 | 0.190 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 1 | 2022 | 82 | 0.190 |
Why?
|
Washington | 1 | 2022 | 147 | 0.190 |
Why?
|
Germ Cells | 1 | 2022 | 59 | 0.190 |
Why?
|
Ankle Brachial Index | 1 | 2021 | 37 | 0.190 |
Why?
|
Blood Pressure | 4 | 2025 | 1733 | 0.190 |
Why?
|
Health Behavior | 1 | 2007 | 740 | 0.190 |
Why?
|
Semen Analysis | 4 | 2022 | 13 | 0.180 |
Why?
|
Urologic Surgical Procedures, Male | 2 | 2011 | 29 | 0.180 |
Why?
|
Transcription Factor CHOP | 1 | 2021 | 30 | 0.180 |
Why?
|
Patient Reported Outcome Measures | 2 | 2024 | 359 | 0.180 |
Why?
|
Emulsions | 1 | 2021 | 43 | 0.180 |
Why?
|
Cost-Benefit Analysis | 1 | 2024 | 581 | 0.180 |
Why?
|
Fat Emulsions, Intravenous | 1 | 2021 | 29 | 0.180 |
Why?
|
Inflammation Mediators | 1 | 2024 | 500 | 0.180 |
Why?
|
Endometrial Neoplasms | 1 | 2023 | 164 | 0.180 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 255 | 0.180 |
Why?
|
Linear Models | 7 | 2019 | 816 | 0.180 |
Why?
|
Thinness | 1 | 2021 | 90 | 0.180 |
Why?
|
Genetic Fitness | 1 | 2021 | 54 | 0.170 |
Why?
|
Sexual Behavior | 3 | 2016 | 477 | 0.170 |
Why?
|
Cell Proliferation | 2 | 2009 | 2335 | 0.170 |
Why?
|
Endoplasmic Reticulum Stress | 1 | 2021 | 101 | 0.170 |
Why?
|
Glucose Clamp Technique | 1 | 2021 | 195 | 0.170 |
Why?
|
Pulse Wave Analysis | 1 | 2021 | 251 | 0.170 |
Why?
|
Heat-Shock Proteins | 1 | 2021 | 131 | 0.170 |
Why?
|
Dominican Republic | 2 | 2010 | 22 | 0.170 |
Why?
|
Drug Combinations | 3 | 2016 | 323 | 0.170 |
Why?
|
Biomarkers, Tumor | 1 | 2007 | 1182 | 0.170 |
Why?
|
Vitamins | 1 | 2021 | 172 | 0.170 |
Why?
|
Obesity, Abdominal | 2 | 2022 | 47 | 0.170 |
Why?
|
Spermatozoa | 3 | 2022 | 91 | 0.170 |
Why?
|
RNA, Messenger | 6 | 2011 | 2674 | 0.170 |
Why?
|
Coitus | 2 | 2022 | 25 | 0.170 |
Why?
|
Choice Behavior | 1 | 2021 | 164 | 0.170 |
Why?
|
Electronics | 1 | 2000 | 73 | 0.170 |
Why?
|
Lipoproteins, HDL | 3 | 2015 | 85 | 0.170 |
Why?
|
Fibroblast Growth Factors | 1 | 2021 | 171 | 0.170 |
Why?
|
Down-Regulation | 5 | 2019 | 629 | 0.170 |
Why?
|
Ethics, Medical | 1 | 2000 | 78 | 0.160 |
Why?
|
Growth Hormone | 2 | 2022 | 96 | 0.160 |
Why?
|
Puberty | 2 | 2019 | 143 | 0.160 |
Why?
|
Osteoporosis, Postmenopausal | 2 | 2011 | 40 | 0.160 |
Why?
|
Leptin | 3 | 2022 | 218 | 0.160 |
Why?
|
Pre-Eclampsia | 2 | 2018 | 183 | 0.160 |
Why?
|
Gonadotropins, Pituitary | 4 | 2011 | 22 | 0.160 |
Why?
|
Gene Expression | 3 | 2021 | 1462 | 0.160 |
Why?
|
Hypertension | 2 | 2024 | 1238 | 0.160 |
Why?
|
Acculturation | 2 | 2010 | 50 | 0.160 |
Why?
|
Cell Nucleolus | 2 | 2010 | 17 | 0.160 |
Why?
|
Erectile Dysfunction | 1 | 2019 | 39 | 0.160 |
Why?
|
Gene Expression Regulation, Developmental | 3 | 2015 | 815 | 0.160 |
Why?
|
Spermatogenesis | 1 | 2019 | 62 | 0.160 |
Why?
|
Surgeons | 1 | 2023 | 274 | 0.160 |
Why?
|
Decidua | 1 | 2019 | 23 | 0.160 |
Why?
|
Adiponectin | 3 | 2022 | 234 | 0.160 |
Why?
|
Sperm Count | 4 | 2022 | 17 | 0.160 |
Why?
|
Menstruation Disturbances | 1 | 2018 | 12 | 0.150 |
Why?
|
Ovarian Diseases | 3 | 1993 | 12 | 0.150 |
Why?
|
Allostasis | 1 | 2018 | 16 | 0.150 |
Why?
|
Ethics Committees, Research | 1 | 2018 | 41 | 0.150 |
Why?
|
Feeding Behavior | 1 | 2024 | 617 | 0.150 |
Why?
|
Carotid Arteries | 1 | 2020 | 206 | 0.150 |
Why?
|
Waist Circumference | 5 | 2022 | 138 | 0.150 |
Why?
|
Adrenal Glands | 1 | 1998 | 71 | 0.150 |
Why?
|
Genitalia | 1 | 2018 | 30 | 0.150 |
Why?
|
Precision Medicine | 1 | 2022 | 383 | 0.150 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2002 | 411 | 0.150 |
Why?
|
Decision Support Techniques | 1 | 2022 | 398 | 0.140 |
Why?
|
Periodicity | 8 | 2016 | 55 | 0.140 |
Why?
|
Child Behavior | 1 | 2020 | 236 | 0.140 |
Why?
|
Placebos | 2 | 2015 | 201 | 0.140 |
Why?
|
Keratin-18 | 1 | 2017 | 10 | 0.140 |
Why?
|
Religion | 1 | 2018 | 68 | 0.140 |
Why?
|
Clinical Protocols | 1 | 2018 | 253 | 0.140 |
Why?
|
Comorbidity | 5 | 2014 | 1540 | 0.140 |
Why?
|
Phytotherapy | 1 | 2017 | 76 | 0.140 |
Why?
|
Adult Survivors of Child Abuse | 1 | 2017 | 26 | 0.140 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2015 | 756 | 0.140 |
Why?
|
Autonomic Nervous System Diseases | 1 | 2017 | 34 | 0.140 |
Why?
|
Brachial Artery | 1 | 2018 | 206 | 0.130 |
Why?
|
Models, Biological | 5 | 2016 | 1693 | 0.130 |
Why?
|
Receptors, Leptin | 2 | 2013 | 23 | 0.130 |
Why?
|
Body Weight | 4 | 2015 | 931 | 0.130 |
Why?
|
Disease Progression | 4 | 2020 | 2603 | 0.130 |
Why?
|
Vaginal Creams, Foams, and Jellies | 1 | 2016 | 4 | 0.130 |
Why?
|
Regional Blood Flow | 1 | 2018 | 462 | 0.130 |
Why?
|
Orgasm | 1 | 2016 | 6 | 0.130 |
Why?
|
Antidepressive Agents | 1 | 2018 | 221 | 0.130 |
Why?
|
Evidence-Based Practice | 1 | 2018 | 213 | 0.130 |
Why?
|
Heart | 1 | 2020 | 638 | 0.130 |
Why?
|
Oxytocics | 1 | 2016 | 14 | 0.130 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2016 | 28 | 0.130 |
Why?
|
Feeding and Eating Disorders | 1 | 2018 | 130 | 0.130 |
Why?
|
Societies, Scientific | 1 | 2016 | 46 | 0.130 |
Why?
|
Microbiota | 1 | 2024 | 720 | 0.130 |
Why?
|
Endocrine System Diseases | 1 | 2016 | 32 | 0.130 |
Why?
|
Health Status | 3 | 2023 | 751 | 0.130 |
Why?
|
Antineoplastic Agents | 2 | 2024 | 2058 | 0.130 |
Why?
|
Causality | 2 | 2014 | 114 | 0.130 |
Why?
|
Fluoroimmunoassay | 2 | 1999 | 3 | 0.120 |
Why?
|
Confidence Intervals | 4 | 2011 | 318 | 0.120 |
Why?
|
Chromatography, Liquid | 2 | 2015 | 374 | 0.120 |
Why?
|
Chlamydia trachomatis | 1 | 2015 | 46 | 0.120 |
Why?
|
Gene Expression Profiling | 2 | 2015 | 1687 | 0.120 |
Why?
|
Hirsutism | 2 | 2017 | 12 | 0.120 |
Why?
|
Autoantibodies | 2 | 2024 | 1463 | 0.120 |
Why?
|
Oxytocin | 1 | 2016 | 48 | 0.120 |
Why?
|
Child Development | 1 | 2020 | 452 | 0.120 |
Why?
|
Infant | 15 | 2024 | 8913 | 0.120 |
Why?
|
Body Constitution | 3 | 2004 | 53 | 0.120 |
Why?
|
Intrauterine Devices, Medicated | 1 | 2015 | 28 | 0.120 |
Why?
|
Observational Studies as Topic | 1 | 2016 | 108 | 0.120 |
Why?
|
Mobility Limitation | 1 | 2015 | 62 | 0.120 |
Why?
|
Societies, Medical | 3 | 2017 | 749 | 0.120 |
Why?
|
Genome-Wide Association Study | 1 | 2022 | 1337 | 0.120 |
Why?
|
Stress, Physiological | 1 | 2018 | 412 | 0.120 |
Why?
|
Patient Dropouts | 1 | 2015 | 65 | 0.120 |
Why?
|
Fetal Growth Retardation | 2 | 2019 | 543 | 0.120 |
Why?
|
Drug Approval | 1 | 2015 | 86 | 0.120 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2009 | 1565 | 0.120 |
Why?
|
Limit of Detection | 1 | 2015 | 55 | 0.120 |
Why?
|
Migraine Disorders | 1 | 2016 | 85 | 0.120 |
Why?
|
Algorithms | 4 | 2011 | 1616 | 0.120 |
Why?
|
Phosphoprotein Phosphatases | 1 | 2015 | 67 | 0.120 |
Why?
|
Vasodilation | 1 | 2018 | 478 | 0.120 |
Why?
|
Antibodies, Bacterial | 1 | 2015 | 136 | 0.120 |
Why?
|
Survival Analysis | 4 | 2014 | 1265 | 0.120 |
Why?
|
Adaptation, Physiological | 1 | 2018 | 514 | 0.120 |
Why?
|
Contraindications | 1 | 2014 | 88 | 0.120 |
Why?
|
Chlamydia Infections | 1 | 2015 | 73 | 0.120 |
Why?
|
Air Pollution | 1 | 2017 | 212 | 0.110 |
Why?
|
United States Food and Drug Administration | 1 | 2015 | 198 | 0.110 |
Why?
|
Cellular Microenvironment | 1 | 2015 | 79 | 0.110 |
Why?
|
Depressive Disorder, Major | 1 | 2018 | 347 | 0.110 |
Why?
|
Diabetes, Gestational | 1 | 2018 | 307 | 0.110 |
Why?
|
Physical Fitness | 1 | 2015 | 203 | 0.110 |
Why?
|
Immunoglobulin G | 2 | 2015 | 837 | 0.110 |
Why?
|
Arthritis, Psoriatic | 1 | 2014 | 20 | 0.110 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2015 | 326 | 0.110 |
Why?
|
Laparoscopy | 1 | 2018 | 454 | 0.110 |
Why?
|
Predictive Value of Tests | 4 | 2016 | 1936 | 0.110 |
Why?
|
Sperm Motility | 3 | 2022 | 30 | 0.110 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2021 | 1190 | 0.110 |
Why?
|
Electronic Health Records | 1 | 2021 | 967 | 0.110 |
Why?
|
Creatinine | 3 | 2022 | 475 | 0.110 |
Why?
|
Oocytes | 2 | 2011 | 175 | 0.110 |
Why?
|
Fatigue | 1 | 2015 | 320 | 0.110 |
Why?
|
Child, Preschool | 16 | 2020 | 10373 | 0.110 |
Why?
|
Aged, 80 and over | 4 | 2015 | 7040 | 0.110 |
Why?
|
Cluster Analysis | 1 | 2015 | 478 | 0.110 |
Why?
|
Bone Marrow Transplantation | 4 | 1999 | 268 | 0.110 |
Why?
|
Range of Motion, Articular | 1 | 2015 | 387 | 0.110 |
Why?
|
Methadone | 2 | 2011 | 90 | 0.100 |
Why?
|
Muscle Strength | 1 | 2015 | 308 | 0.100 |
Why?
|
Nerve Tissue Proteins | 3 | 2011 | 567 | 0.100 |
Why?
|
Rats | 3 | 2019 | 5168 | 0.100 |
Why?
|
Contraceptives, Oral | 2 | 2003 | 39 | 0.100 |
Why?
|
Chi-Square Distribution | 4 | 2015 | 512 | 0.100 |
Why?
|
Retinol-Binding Proteins, Plasma | 1 | 2012 | 6 | 0.100 |
Why?
|
Anxiety Disorders | 1 | 2015 | 347 | 0.100 |
Why?
|
Drug Administration Schedule | 2 | 2012 | 757 | 0.100 |
Why?
|
Heart Diseases | 1 | 2015 | 345 | 0.100 |
Why?
|
China | 4 | 2011 | 191 | 0.100 |
Why?
|
Varicocele | 1 | 2011 | 10 | 0.100 |
Why?
|
Heart Rate | 1 | 2016 | 804 | 0.100 |
Why?
|
Placenta Diseases | 1 | 2011 | 14 | 0.100 |
Why?
|
Tissue Banks | 1 | 2011 | 15 | 0.100 |
Why?
|
Receptors, Somatomedin | 1 | 2011 | 4 | 0.100 |
Why?
|
Epithelial Cells | 2 | 2009 | 1036 | 0.090 |
Why?
|
Receptors, Glucagon | 1 | 2011 | 28 | 0.090 |
Why?
|
Somatomedins | 1 | 2011 | 28 | 0.090 |
Why?
|
Models, Theoretical | 1 | 2015 | 546 | 0.090 |
Why?
|
Receptor, trkA | 1 | 2011 | 16 | 0.090 |
Why?
|
Siblings | 2 | 2009 | 215 | 0.090 |
Why?
|
Skin | 1 | 2016 | 717 | 0.090 |
Why?
|
Narcotics | 1 | 2011 | 47 | 0.090 |
Why?
|
Glucagon | 1 | 2011 | 105 | 0.090 |
Why?
|
Gene Expression Regulation | 2 | 2011 | 2506 | 0.090 |
Why?
|
Actigraphy | 3 | 2017 | 90 | 0.090 |
Why?
|
Pelvic Organ Prolapse | 1 | 2011 | 45 | 0.090 |
Why?
|
CD4 Lymphocyte Count | 3 | 2006 | 265 | 0.090 |
Why?
|
Protease Inhibitors | 1 | 2011 | 103 | 0.090 |
Why?
|
Skin Physiological Phenomena | 1 | 2010 | 25 | 0.090 |
Why?
|
Sperm Injections, Intracytoplasmic | 1 | 2010 | 7 | 0.090 |
Why?
|
Fetal Diseases | 1 | 2011 | 148 | 0.090 |
Why?
|
Japan | 3 | 2011 | 98 | 0.090 |
Why?
|
Superovulation | 3 | 2012 | 8 | 0.090 |
Why?
|
Hip Fractures | 1 | 2011 | 82 | 0.090 |
Why?
|
Decision Trees | 1 | 2010 | 89 | 0.090 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2011 | 371 | 0.080 |
Why?
|
Environment | 2 | 2003 | 347 | 0.080 |
Why?
|
Career Mobility | 1 | 2010 | 68 | 0.080 |
Why?
|
Minisatellite Repeats | 1 | 2009 | 40 | 0.080 |
Why?
|
Lithium Chloride | 1 | 2009 | 11 | 0.080 |
Why?
|
Health Promotion | 1 | 2015 | 717 | 0.080 |
Why?
|
Comprehension | 1 | 2011 | 166 | 0.080 |
Why?
|
Quality Control | 2 | 2000 | 156 | 0.080 |
Why?
|
Memory | 1 | 2011 | 231 | 0.080 |
Why?
|
Blastocyst | 1 | 2009 | 47 | 0.080 |
Why?
|
Glucocorticoids | 1 | 1993 | 575 | 0.080 |
Why?
|
HIV Seropositivity | 2 | 2011 | 119 | 0.080 |
Why?
|
Magnetic Resonance Angiography | 1 | 2011 | 237 | 0.080 |
Why?
|
Proteomics | 1 | 2015 | 1004 | 0.080 |
Why?
|
Chorionic Gonadotropin, beta Subunit, Human | 2 | 1999 | 16 | 0.080 |
Why?
|
Perception | 1 | 2011 | 337 | 0.080 |
Why?
|
Sleep Apnea Syndromes | 1 | 2009 | 78 | 0.080 |
Why?
|
Wounds and Injuries | 1 | 2015 | 714 | 0.080 |
Why?
|
Vaginitis | 1 | 2008 | 2 | 0.080 |
Why?
|
Nuclear Pore | 1 | 2008 | 16 | 0.080 |
Why?
|
Osteoprotegerin | 1 | 2008 | 25 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2008 | 1943 | 0.080 |
Why?
|
Embryo Implantation | 1 | 2008 | 27 | 0.070 |
Why?
|
Autoimmune Diseases | 2 | 2003 | 423 | 0.070 |
Why?
|
Mutation | 3 | 2009 | 3692 | 0.070 |
Why?
|
Uterine Prolapse | 1 | 2008 | 14 | 0.070 |
Why?
|
Birth Weight | 2 | 2024 | 498 | 0.070 |
Why?
|
Infant, Low Birth Weight | 2 | 2019 | 132 | 0.070 |
Why?
|
Coronary Disease | 2 | 2012 | 384 | 0.070 |
Why?
|
Analysis of Variance | 4 | 2019 | 1271 | 0.070 |
Why?
|
Androstenedione | 2 | 1999 | 11 | 0.070 |
Why?
|
Anthropometry | 1 | 2008 | 204 | 0.070 |
Why?
|
Social Class | 1 | 2009 | 259 | 0.070 |
Why?
|
Data Collection | 1 | 2010 | 649 | 0.070 |
Why?
|
Skin Absorption | 1 | 2007 | 10 | 0.070 |
Why?
|
Tissue Distribution | 1 | 2007 | 290 | 0.070 |
Why?
|
Combined Modality Therapy | 5 | 2021 | 1209 | 0.070 |
Why?
|
Self Report | 3 | 2018 | 801 | 0.070 |
Why?
|
Cultural Characteristics | 1 | 2007 | 62 | 0.070 |
Why?
|
Receptors, Steroid | 1 | 2007 | 48 | 0.070 |
Why?
|
Hypoglycemia | 1 | 2011 | 426 | 0.070 |
Why?
|
Interpersonal Relations | 1 | 2010 | 386 | 0.070 |
Why?
|
Research Design | 2 | 2011 | 1038 | 0.070 |
Why?
|
Administration, Topical | 1 | 2007 | 144 | 0.070 |
Why?
|
Asparaginase | 3 | 2001 | 29 | 0.070 |
Why?
|
Proteins | 3 | 1989 | 936 | 0.070 |
Why?
|
Patient Satisfaction | 2 | 2021 | 644 | 0.070 |
Why?
|
Relaxin | 2 | 1998 | 18 | 0.070 |
Why?
|
Tissue Donors | 1 | 2009 | 386 | 0.060 |
Why?
|
Age Distribution | 2 | 2004 | 376 | 0.060 |
Why?
|
Lipid Metabolism | 1 | 2009 | 493 | 0.060 |
Why?
|
Gonadal Hormones | 1 | 2005 | 6 | 0.060 |
Why?
|
Spouses | 1 | 2007 | 99 | 0.060 |
Why?
|
Phosphorylation | 2 | 2021 | 1681 | 0.060 |
Why?
|
Preoptic Area | 1 | 2005 | 6 | 0.060 |
Why?
|
Inhibin-beta Subunits | 1 | 2005 | 5 | 0.060 |
Why?
|
Anorexia Nervosa | 1 | 2006 | 75 | 0.060 |
Why?
|
Population Surveillance | 1 | 2008 | 427 | 0.060 |
Why?
|
Maternal Age | 2 | 2022 | 122 | 0.060 |
Why?
|
Interleukin-1 | 1 | 2009 | 961 | 0.060 |
Why?
|
Libido | 1 | 2005 | 24 | 0.060 |
Why?
|
Internet | 2 | 2015 | 618 | 0.060 |
Why?
|
Health Services Misuse | 1 | 2005 | 36 | 0.060 |
Why?
|
Iodide Peroxidase | 1 | 2024 | 29 | 0.060 |
Why?
|
Arthritis, Rheumatoid | 1 | 2014 | 1108 | 0.060 |
Why?
|
Blastomeres | 1 | 2004 | 10 | 0.060 |
Why?
|
Nuclear Proteins | 3 | 2022 | 648 | 0.060 |
Why?
|
Endoplasmic Reticulum | 1 | 2007 | 260 | 0.060 |
Why?
|
Absorptiometry, Photon | 3 | 2015 | 250 | 0.060 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 2 | 2001 | 39 | 0.060 |
Why?
|
Psychiatric Status Rating Scales | 2 | 2017 | 523 | 0.060 |
Why?
|
Infusions, Intravenous | 3 | 1994 | 384 | 0.060 |
Why?
|
Vulnerable Populations | 1 | 2005 | 157 | 0.060 |
Why?
|
Apoptosis | 2 | 2017 | 2437 | 0.060 |
Why?
|
Bone Marrow | 1 | 2005 | 267 | 0.060 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2005 | 113 | 0.060 |
Why?
|
Proportional Hazards Models | 1 | 2007 | 1208 | 0.050 |
Why?
|
Sex Characteristics | 3 | 2019 | 727 | 0.050 |
Why?
|
Central Nervous System | 1 | 2005 | 255 | 0.050 |
Why?
|
Fetal Macrosomia | 1 | 2024 | 61 | 0.050 |
Why?
|
Mass Screening | 1 | 2011 | 1152 | 0.050 |
Why?
|
Glutamic Acid | 1 | 2005 | 231 | 0.050 |
Why?
|
Minority Groups | 1 | 2005 | 251 | 0.050 |
Why?
|
MicroRNAs | 1 | 2009 | 671 | 0.050 |
Why?
|
Elasticity | 2 | 2016 | 200 | 0.050 |
Why?
|
Sugars | 1 | 2023 | 37 | 0.050 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2023 | 123 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 937 | 0.050 |
Why?
|
Melphalan | 2 | 1999 | 29 | 0.050 |
Why?
|
Pituitary Hormones | 1 | 2022 | 16 | 0.050 |
Why?
|
Follicular Atresia | 1 | 2002 | 4 | 0.050 |
Why?
|
Remission Induction | 4 | 2009 | 269 | 0.050 |
Why?
|
Gynecologic Surgical Procedures | 1 | 2002 | 54 | 0.050 |
Why?
|
alpha-Amylases | 1 | 2022 | 16 | 0.050 |
Why?
|
Whole-Body Irradiation | 2 | 1999 | 75 | 0.050 |
Why?
|
Thyroid Hormones | 1 | 2022 | 54 | 0.050 |
Why?
|
Snoring | 1 | 2021 | 12 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 1 | 2011 | 2521 | 0.050 |
Why?
|
Receptors, Estrogen | 1 | 2004 | 428 | 0.050 |
Why?
|
Eukaryotic Initiation Factor-2 | 1 | 2021 | 26 | 0.050 |
Why?
|
Breast | 1 | 2022 | 152 | 0.050 |
Why?
|
Computers | 2 | 2000 | 65 | 0.050 |
Why?
|
Lipopolysaccharide Receptors | 1 | 2022 | 88 | 0.050 |
Why?
|
Maternal-Child Nursing | 1 | 2001 | 11 | 0.050 |
Why?
|
Nursing Methodology Research | 1 | 2001 | 46 | 0.050 |
Why?
|
Prevotella | 1 | 2021 | 14 | 0.050 |
Why?
|
Canada | 1 | 2022 | 345 | 0.050 |
Why?
|
Open Reading Frames | 1 | 2021 | 116 | 0.050 |
Why?
|
Grief | 1 | 2001 | 36 | 0.050 |
Why?
|
X Chromosome | 1 | 2001 | 51 | 0.040 |
Why?
|
Anger | 1 | 2001 | 56 | 0.040 |
Why?
|
Pulmonary Blastoma | 1 | 2000 | 8 | 0.040 |
Why?
|
Body Surface Area | 1 | 2020 | 34 | 0.040 |
Why?
|
Radiography | 2 | 2014 | 864 | 0.040 |
Why?
|
Insemination | 1 | 2020 | 1 | 0.040 |
Why?
|
Pleural Neoplasms | 1 | 2000 | 23 | 0.040 |
Why?
|
Heparin | 1 | 2022 | 240 | 0.040 |
Why?
|
Illinois | 1 | 2020 | 39 | 0.040 |
Why?
|
Gestational Age | 1 | 2024 | 862 | 0.040 |
Why?
|
Blood Volume | 1 | 2020 | 60 | 0.040 |
Why?
|
Paper | 1 | 2000 | 10 | 0.040 |
Why?
|
Chicago | 1 | 2020 | 57 | 0.040 |
Why?
|
Gestures | 1 | 2020 | 6 | 0.040 |
Why?
|
Reproducibility of Results | 3 | 2018 | 3023 | 0.040 |
Why?
|
Cell Line | 2 | 2021 | 2731 | 0.040 |
Why?
|
Antihypertensive Agents | 1 | 2024 | 486 | 0.040 |
Why?
|
Leukemia, Myelomonocytic, Acute | 1 | 1999 | 7 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2014 | 857 | 0.040 |
Why?
|
Thrombin | 1 | 2000 | 142 | 0.040 |
Why?
|
Personal Autonomy | 1 | 2000 | 48 | 0.040 |
Why?
|
Observer Variation | 1 | 2000 | 315 | 0.040 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 1999 | 69 | 0.040 |
Why?
|
Cell Division | 1 | 2021 | 779 | 0.040 |
Why?
|
Sexual Maturation | 1 | 2019 | 52 | 0.040 |
Why?
|
Ultrasonography, Prenatal | 1 | 2021 | 266 | 0.040 |
Why?
|
Sex Factors | 2 | 2019 | 1949 | 0.040 |
Why?
|
Pregnant Women | 1 | 2000 | 118 | 0.040 |
Why?
|
Energy Metabolism | 2 | 2022 | 836 | 0.040 |
Why?
|
Histiocytosis, Non-Langerhans-Cell | 1 | 1999 | 5 | 0.040 |
Why?
|
Gene Deletion | 1 | 2001 | 372 | 0.040 |
Why?
|
Protein Biosynthesis | 1 | 2021 | 397 | 0.040 |
Why?
|
Chromosome Breakage | 1 | 1999 | 21 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2008 | 1820 | 0.040 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 1999 | 39 | 0.040 |
Why?
|
Clinical Decision-Making | 1 | 2022 | 302 | 0.040 |
Why?
|
Triglycerides | 2 | 2017 | 524 | 0.040 |
Why?
|
Chromosome Inversion | 1 | 1999 | 17 | 0.040 |
Why?
|
Educational Status | 2 | 2012 | 470 | 0.040 |
Why?
|
Protein Processing, Post-Translational | 1 | 2021 | 450 | 0.040 |
Why?
|
Italy | 3 | 2009 | 98 | 0.040 |
Why?
|
Diet | 2 | 2023 | 1200 | 0.040 |
Why?
|
Insurance, Health | 1 | 2001 | 271 | 0.040 |
Why?
|
Neurons | 1 | 2007 | 1448 | 0.040 |
Why?
|
Needs Assessment | 1 | 2001 | 360 | 0.040 |
Why?
|
Hyperthyroidism | 1 | 2018 | 28 | 0.040 |
Why?
|
Genetic Testing | 1 | 2001 | 427 | 0.040 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2021 | 521 | 0.040 |
Why?
|
Injections, Intravenous | 2 | 1990 | 193 | 0.040 |
Why?
|
Microinjections | 1 | 1998 | 76 | 0.040 |
Why?
|
Diagnostic Techniques, Obstetrical and Gynecological | 2 | 2008 | 6 | 0.040 |
Why?
|
Organ Size | 2 | 2010 | 440 | 0.040 |
Why?
|
Glucuronates | 1 | 2017 | 4 | 0.040 |
Why?
|
Cardiovascular System | 1 | 2019 | 139 | 0.040 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2021 | 239 | 0.040 |
Why?
|
Conservative Treatment | 1 | 2018 | 34 | 0.040 |
Why?
|
Transaminases | 1 | 2017 | 23 | 0.040 |
Why?
|
Islets of Langerhans | 1 | 2004 | 790 | 0.040 |
Why?
|
Cholesterol | 1 | 2019 | 406 | 0.040 |
Why?
|
Receptors, Angiotensin | 1 | 1997 | 12 | 0.030 |
Why?
|
Immunologic Tests | 1 | 1997 | 16 | 0.030 |
Why?
|
Disease-Free Survival | 4 | 2001 | 656 | 0.030 |
Why?
|
Public Health | 1 | 2022 | 486 | 0.030 |
Why?
|
Thrombosis | 1 | 2000 | 321 | 0.030 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 1997 | 69 | 0.030 |
Why?
|
Pregnancy Tests | 1 | 2017 | 8 | 0.030 |
Why?
|
Dietary Supplements | 1 | 2021 | 529 | 0.030 |
Why?
|
Vehicle Emissions | 1 | 2017 | 56 | 0.030 |
Why?
|
Biological Assay | 1 | 2017 | 118 | 0.030 |
Why?
|
Biopsy | 1 | 2000 | 1085 | 0.030 |
Why?
|
Severity of Illness Index | 2 | 2018 | 2736 | 0.030 |
Why?
|
Genes | 1 | 1997 | 226 | 0.030 |
Why?
|
Hypertriglyceridemia | 1 | 2017 | 39 | 0.030 |
Why?
|
Molecular Weight | 3 | 2013 | 331 | 0.030 |
Why?
|
Hepatitis C | 2 | 2011 | 233 | 0.030 |
Why?
|
Transdermal Patch | 1 | 2016 | 15 | 0.030 |
Why?
|
Mice | 4 | 2021 | 16579 | 0.030 |
Why?
|
Hyperprolactinemia | 1 | 2016 | 4 | 0.030 |
Why?
|
Galvanic Skin Response | 1 | 2016 | 28 | 0.030 |
Why?
|
Goiter | 1 | 1996 | 4 | 0.030 |
Why?
|
Quality of Health Care | 1 | 2001 | 607 | 0.030 |
Why?
|
Substance Abuse, Intravenous | 2 | 2008 | 106 | 0.030 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2019 | 380 | 0.030 |
Why?
|
Hospitals, Pediatric | 1 | 2019 | 516 | 0.030 |
Why?
|
Catheters, Indwelling | 2 | 1993 | 74 | 0.030 |
Why?
|
Serologic Tests | 1 | 2015 | 50 | 0.030 |
Why?
|
Alcohol Drinking | 2 | 2012 | 749 | 0.030 |
Why?
|
Hypothyroidism | 1 | 1996 | 71 | 0.030 |
Why?
|
Pandemics | 1 | 2024 | 1487 | 0.030 |
Why?
|
Statistics, Nonparametric | 2 | 2011 | 423 | 0.030 |
Why?
|
Transcriptome | 1 | 2021 | 881 | 0.030 |
Why?
|
Neuroblastoma | 1 | 1996 | 154 | 0.030 |
Why?
|
Histiocytosis, Langerhans-Cell | 1 | 1995 | 37 | 0.030 |
Why?
|
Cranial Irradiation | 2 | 2009 | 68 | 0.030 |
Why?
|
Neovascularization, Physiologic | 1 | 2016 | 172 | 0.030 |
Why?
|
Genetic Markers | 2 | 2011 | 339 | 0.030 |
Why?
|
Registries | 2 | 2020 | 1878 | 0.030 |
Why?
|
Qualitative Research | 1 | 2021 | 1205 | 0.030 |
Why?
|
Cyclosporine | 1 | 1995 | 168 | 0.030 |
Why?
|
Peptide Fragments | 1 | 1999 | 685 | 0.030 |
Why?
|
Myocardium | 1 | 2020 | 970 | 0.030 |
Why?
|
Antibodies, Monoclonal | 2 | 2014 | 1355 | 0.030 |
Why?
|
Deafness | 1 | 1996 | 80 | 0.030 |
Why?
|
Certolizumab Pegol | 1 | 2014 | 3 | 0.030 |
Why?
|
Vincristine | 3 | 2001 | 110 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2018 | 1416 | 0.030 |
Why?
|
Etanercept | 1 | 2014 | 58 | 0.030 |
Why?
|
Osmolar Concentration | 1 | 1994 | 162 | 0.030 |
Why?
|
Adalimumab | 1 | 2014 | 44 | 0.030 |
Why?
|
Freezing | 1 | 1994 | 86 | 0.030 |
Why?
|
Glycerol | 1 | 1994 | 87 | 0.030 |
Why?
|
Drug Stability | 1 | 1994 | 144 | 0.030 |
Why?
|
Anions | 1 | 2013 | 30 | 0.030 |
Why?
|
Infliximab | 1 | 2014 | 100 | 0.030 |
Why?
|
Immunoglobulin Fab Fragments | 1 | 2014 | 70 | 0.030 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2014 | 162 | 0.030 |
Why?
|
Medical Records | 1 | 2014 | 169 | 0.030 |
Why?
|
Air Pollutants | 1 | 2017 | 311 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 814 | 0.030 |
Why?
|
Molecular Conformation | 1 | 2013 | 139 | 0.030 |
Why?
|
Carrier Proteins | 1 | 1997 | 731 | 0.030 |
Why?
|
Electrocardiography | 1 | 2016 | 607 | 0.030 |
Why?
|
Anal Canal | 1 | 1993 | 89 | 0.030 |
Why?
|
Cell Survival | 2 | 2007 | 1077 | 0.030 |
Why?
|
Menstruation-Inducing Agents | 1 | 2012 | 1 | 0.030 |
Why?
|
Urinary Tract Infections | 1 | 2014 | 150 | 0.020 |
Why?
|
Growth Differentiation Factor 9 | 1 | 2011 | 4 | 0.020 |
Why?
|
Coffee | 1 | 2012 | 15 | 0.020 |
Why?
|
Rectal Neoplasms | 1 | 1993 | 136 | 0.020 |
Why?
|
Pituitary Gland, Anterior | 1 | 2011 | 38 | 0.020 |
Why?
|
Tea | 1 | 2012 | 20 | 0.020 |
Why?
|
Oogenesis | 1 | 2011 | 20 | 0.020 |
Why?
|
Women | 1 | 2012 | 52 | 0.020 |
Why?
|
Cystocele | 1 | 2011 | 1 | 0.020 |
Why?
|
Alcoholic Beverages | 1 | 2012 | 20 | 0.020 |
Why?
|
Rectocele | 1 | 2011 | 3 | 0.020 |
Why?
|
Mutation, Missense | 2 | 2006 | 317 | 0.020 |
Why?
|
Placentation | 1 | 2011 | 44 | 0.020 |
Why?
|
Fetal Death | 1 | 2011 | 55 | 0.020 |
Why?
|
Pregnancy Proteins | 1 | 2011 | 37 | 0.020 |
Why?
|
Ulna Fractures | 1 | 2011 | 14 | 0.020 |
Why?
|
Receptors, Nerve Growth Factor | 1 | 2011 | 16 | 0.020 |
Why?
|
Nerve Growth Factor | 1 | 2011 | 27 | 0.020 |
Why?
|
Body Height | 1 | 2012 | 192 | 0.020 |
Why?
|
Receptor, trkB | 1 | 2011 | 31 | 0.020 |
Why?
|
Postoperative Complications | 2 | 2001 | 2479 | 0.020 |
Why?
|
Colon | 1 | 1993 | 251 | 0.020 |
Why?
|
Progesterone Congeners | 1 | 2010 | 16 | 0.020 |
Why?
|
Heterozygote | 1 | 2011 | 266 | 0.020 |
Why?
|
Waist-Hip Ratio | 1 | 2010 | 36 | 0.020 |
Why?
|
Radius Fractures | 1 | 2011 | 58 | 0.020 |
Why?
|
Radioimmunoassay | 1 | 2010 | 169 | 0.020 |
Why?
|
Brain-Derived Neurotrophic Factor | 1 | 2011 | 111 | 0.020 |
Why?
|
Cross Reactions | 1 | 2010 | 127 | 0.020 |
Why?
|
Dominica | 1 | 2010 | 1 | 0.020 |
Why?
|
Spinal Fractures | 1 | 2011 | 81 | 0.020 |
Why?
|
Proinsulin | 1 | 2010 | 52 | 0.020 |
Why?
|
Informed Consent | 1 | 2011 | 174 | 0.020 |
Why?
|
Daunorubicin | 2 | 2001 | 25 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2011 | 304 | 0.020 |
Why?
|
Risk Reduction Behavior | 1 | 2012 | 208 | 0.020 |
Why?
|
Herpes Zoster | 1 | 2014 | 317 | 0.020 |
Why?
|
Hematology | 1 | 2009 | 14 | 0.020 |
Why?
|
Survival Rate | 2 | 2009 | 1872 | 0.020 |
Why?
|
Infusion Pumps | 1 | 1989 | 31 | 0.020 |
Why?
|
Pulse Therapy, Drug | 1 | 2009 | 7 | 0.020 |
Why?
|
Ambulatory Care | 1 | 1993 | 506 | 0.020 |
Why?
|
Colorado | 1 | 2019 | 4392 | 0.020 |
Why?
|
Culture Techniques | 1 | 1989 | 81 | 0.020 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 1989 | 96 | 0.020 |
Why?
|
Cyclin D1 | 1 | 2009 | 63 | 0.020 |
Why?
|
Glycogen Synthase Kinase 3 beta | 1 | 2009 | 67 | 0.020 |
Why?
|
Polyethylene Glycols | 1 | 2014 | 597 | 0.020 |
Why?
|
Prednisone | 2 | 2001 | 236 | 0.020 |
Why?
|
Glycogen Synthase Kinase 3 | 1 | 2009 | 79 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2009 | 187 | 0.020 |
Why?
|
Polysomnography | 1 | 2009 | 159 | 0.020 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2014 | 759 | 0.020 |
Why?
|
West Indies | 1 | 2008 | 4 | 0.020 |
Why?
|
Safety | 1 | 1990 | 329 | 0.020 |
Why?
|
Tartrate-Resistant Acid Phosphatase | 1 | 2008 | 5 | 0.020 |
Why?
|
Acid Phosphatase | 1 | 2008 | 20 | 0.020 |
Why?
|
RANK Ligand | 1 | 2008 | 27 | 0.020 |
Why?
|
Hyperhidrosis | 1 | 2008 | 6 | 0.020 |
Why?
|
Estrogen Antagonists | 1 | 2008 | 45 | 0.020 |
Why?
|
Menorrhagia | 1 | 2008 | 20 | 0.020 |
Why?
|
Papio | 1 | 2008 | 91 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 2 | 2005 | 2245 | 0.020 |
Why?
|
Pelvic Floor | 1 | 2008 | 23 | 0.020 |
Why?
|
Chronic Disease | 1 | 2014 | 1701 | 0.020 |
Why?
|
Collagen Type I | 1 | 2008 | 118 | 0.020 |
Why?
|
Alkaline Phosphatase | 1 | 2008 | 142 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2000 | 2323 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2008 | 374 | 0.020 |
Why?
|
Transplantation, Autologous | 2 | 1999 | 215 | 0.020 |
Why?
|
Microscopy, Immunoelectron | 1 | 2007 | 43 | 0.020 |
Why?
|
Medical Oncology | 1 | 2009 | 272 | 0.020 |
Why?
|
Isoenzymes | 1 | 2008 | 304 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2010 | 660 | 0.020 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2008 | 158 | 0.020 |
Why?
|
Cell Line, Transformed | 1 | 2007 | 140 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2008 | 236 | 0.020 |
Why?
|
Transplantation Conditioning | 2 | 1999 | 164 | 0.020 |
Why?
|
Polymorphism, Genetic | 2 | 2000 | 639 | 0.020 |
Why?
|
Myocardial Infarction | 1 | 2014 | 1014 | 0.020 |
Why?
|
Up-Regulation | 1 | 2009 | 826 | 0.020 |
Why?
|
Burkitt Lymphoma | 2 | 2000 | 55 | 0.020 |
Why?
|
Cell Count | 1 | 2007 | 314 | 0.020 |
Why?
|
Obesity, Morbid | 1 | 2010 | 238 | 0.020 |
Why?
|
New York | 1 | 2006 | 123 | 0.020 |
Why?
|
Neuropsychological Tests | 1 | 2011 | 1003 | 0.020 |
Why?
|
Sleep Disorders, Intrinsic | 1 | 2005 | 1 | 0.020 |
Why?
|
Body Fluids | 1 | 1986 | 62 | 0.020 |
Why?
|
Base Sequence | 2 | 2001 | 2134 | 0.020 |
Why?
|
HIV-1 | 1 | 1991 | 840 | 0.020 |
Why?
|
Microdialysis | 1 | 2005 | 51 | 0.020 |
Why?
|
Stroke | 1 | 2014 | 1064 | 0.020 |
Why?
|
Placenta | 1 | 2011 | 714 | 0.020 |
Why?
|
Communication | 1 | 2011 | 838 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2011 | 2752 | 0.010 |
Why?
|
Urban Population | 1 | 2008 | 438 | 0.010 |
Why?
|
Neoplasm, Residual | 1 | 2005 | 118 | 0.010 |
Why?
|
Phosphoproteins | 1 | 2007 | 330 | 0.010 |
Why?
|
Molecular Sequence Data | 2 | 2001 | 2818 | 0.010 |
Why?
|
Genomics | 1 | 2009 | 716 | 0.010 |
Why?
|
Demography | 1 | 2005 | 277 | 0.010 |
Why?
|
Life Change Events | 1 | 2005 | 148 | 0.010 |
Why?
|
Lipoproteins, HDL2 | 1 | 2003 | 2 | 0.010 |
Why?
|
Monitoring, Physiologic | 1 | 1985 | 267 | 0.010 |
Why?
|
Peptides | 1 | 2008 | 909 | 0.010 |
Why?
|
Kinetics | 1 | 1986 | 1616 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2005 | 705 | 0.010 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2005 | 430 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2009 | 4008 | 0.010 |
Why?
|
Polymorphism, Single-Stranded Conformational | 1 | 2001 | 28 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2011 | 5257 | 0.010 |
Why?
|
Estrus | 1 | 2001 | 12 | 0.010 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 1 | 2000 | 13 | 0.010 |
Why?
|
Rest | 1 | 2001 | 123 | 0.010 |
Why?
|
Calcium | 1 | 2007 | 1178 | 0.010 |
Why?
|
Blood Coagulation Tests | 1 | 2000 | 51 | 0.010 |
Why?
|
Injections, Intramuscular | 1 | 2001 | 117 | 0.010 |
Why?
|
Pedigree | 1 | 2001 | 485 | 0.010 |
Why?
|
Terminology as Topic | 1 | 2001 | 199 | 0.010 |
Why?
|
Random Allocation | 1 | 2001 | 346 | 0.010 |
Why?
|
Transplants | 1 | 1999 | 35 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2005 | 1333 | 0.010 |
Why?
|
Immunophenotyping | 1 | 2000 | 312 | 0.010 |
Why?
|
Consanguinity | 1 | 1999 | 47 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2001 | 260 | 0.010 |
Why?
|
Mercaptopurine | 1 | 1998 | 15 | 0.010 |
Why?
|
Thioguanine | 1 | 1998 | 18 | 0.010 |
Why?
|
Leucovorin | 1 | 1998 | 68 | 0.010 |
Why?
|
Cytarabine | 1 | 1998 | 55 | 0.010 |
Why?
|
Pregnancy Trimester, Second | 1 | 1998 | 75 | 0.010 |
Why?
|
Genetic Linkage | 1 | 1999 | 299 | 0.010 |
Why?
|
Pregnancy Trimester, Third | 1 | 1998 | 104 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 1998 | 231 | 0.010 |
Why?
|
Chromosome Aberrations | 1 | 1998 | 147 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2001 | 2041 | 0.010 |
Why?
|
Receptor, Angiotensin, Type 2 | 1 | 1997 | 9 | 0.010 |
Why?
|
Restriction Mapping | 1 | 1997 | 74 | 0.010 |
Why?
|
Doxorubicin | 1 | 1998 | 322 | 0.010 |
Why?
|
Dexamethasone | 1 | 1998 | 336 | 0.010 |
Why?
|
Introns | 1 | 1997 | 245 | 0.010 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 2 | 1987 | 323 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 1997 | 522 | 0.010 |
Why?
|
DNA Mutational Analysis | 1 | 1997 | 386 | 0.010 |
Why?
|
Exons | 1 | 1997 | 337 | 0.010 |
Why?
|
Risk | 1 | 1998 | 852 | 0.010 |
Why?
|
Syndrome | 1 | 1996 | 335 | 0.010 |
Why?
|
Chemical and Drug Induced Liver Injury | 1 | 1996 | 134 | 0.010 |
Why?
|
Drug Resistance | 1 | 1995 | 163 | 0.010 |
Why?
|
Recurrence | 1 | 1996 | 1001 | 0.010 |
Why?
|
Colostomy | 1 | 1993 | 26 | 0.010 |
Why?
|
Liver Diseases | 1 | 1996 | 285 | 0.010 |
Why?
|
Testis | 1 | 1994 | 144 | 0.010 |
Why?
|
Anastomosis, Surgical | 1 | 1993 | 150 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2000 | 2266 | 0.010 |
Why?
|
Lymphoma, AIDS-Related | 1 | 1991 | 14 | 0.010 |
Why?
|
Sarcoma, Kaposi | 1 | 1991 | 76 | 0.010 |
Why?
|
Reoperation | 1 | 1993 | 550 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 1997 | 1398 | 0.010 |
Why?
|
Feedback | 1 | 1990 | 159 | 0.010 |
Why?
|
Carcinoma, Hepatocellular | 1 | 1991 | 269 | 0.010 |
Why?
|
Equipment Contamination | 1 | 1989 | 57 | 0.000 |
Why?
|
Forearm | 1 | 1989 | 119 | 0.000 |
Why?
|
Bacterial Infections | 1 | 1989 | 227 | 0.000 |
Why?
|
Organ Culture Techniques | 1 | 1987 | 144 | 0.000 |
Why?
|
Liver Neoplasms | 1 | 1991 | 640 | 0.000 |
Why?
|
Isoelectric Point | 1 | 1986 | 23 | 0.000 |
Why?
|
Hemoglobins | 1 | 1986 | 336 | 0.000 |
Why?
|
Bacteria | 1 | 1989 | 811 | 0.000 |
Why?
|